<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00921947</url>
  </required_header>
  <id_info>
    <org_study_id>VAX102-09</org_study_id>
    <nct_id>NCT00921947</nct_id>
  </id_info>
  <brief_title>Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults</brief_title>
  <official_title>A Phase II, Randomized, Open-Label Study to Evaluate the Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VaxInnate Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VaxInnate Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To assess the safety, reactogenicity, tolerability, and adverse events (AEs) of the
           VAX102 vaccine in a two dose regimen (Day 0 and Day 28) at the 1.0 µg dose level
           delivered i.m., or the 2.0 µg dose level delivered s.c. in a healthy adult population.

        2. To assess the immunogenicity (anti-M2e serum antibody concentration) of the VAX102
           vaccine in a two dose regimen (Day 0 and Day 28) at the 1.0 µg dose level delivered
           i.m., or the 2.0 µg dose level delivered s.c. as measured by an enzyme-linked
           immunosorbent assay (ELISA) in a healthy adult population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Local and Systemic Symptoms Post Vaccination 1 (Day 0)</measure>
    <time_frame>0 to 7 days after vaccination</time_frame>
    <description>Solicited local and general symptoms experienced within 7 days after vaccination 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Local and Systemic Symptoms Post Vaccination 2 (Day 28)</measure>
    <time_frame>14 days after vaccination</time_frame>
    <description>Solicited local and general symptoms experienced within 14 days after vaccination 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-M2e Serum Antibody Concentration</measure>
    <time_frame>42 days (+/- 2)</time_frame>
    <description>Anti-M2e Serum Antibody Concentration summarized by study visit using the per-protocol population.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>VAX102 IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VAX102 given as 1 µg intramuscular (i.m.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VAX102 SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VAX102 given as a 2 µg subcutaneous (s.c.) dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VAX102</intervention_name>
    <description>Universal M2e influenza vaccine</description>
    <arm_group_label>VAX102 IM</arm_group_label>
    <arm_group_label>VAX102 SC</arm_group_label>
    <other_name>STF2.4xM2e</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult men or women aged 18 to 49 years inclusive.

          -  Able and willing to provide written informed consent to participate.

          -  Healthy, as determined by medical history, physical examination, and vital signs.

          -  Willing to receive the unlicensed (VAX102) vaccine given as an i.m. or s.c. injection.

          -  Willing to provide multiple blood specimens collected by venipuncture.

          -  Females should avoid becoming pregnant during the course of the study

          -  Women of childbearing potential must have a negative urine pregnancy test within 24
             hours preceding receipt of the first and preceding receipt of the second (booster)
             vaccination.

          -  Must exhibit comprehension of the study requirements; expressed availability for the
             required study period and expect to reside in the study area during the entire study
             period, and ability to attend scheduled visits.

        Exclusion Criteria:

          -  Persons under 18 years old or 50 years or older.

          -  Persons with chronic illnesses such as cancer, diabetes, liver or kidney disease.

          -  Person currently pregnant, nursing mothers or planning a pregnancy within one month of
             vaccination.

          -  Persons who have had a prior serious reaction to influenza vaccine.

          -  Persons with a history of anaphylactic-type reaction to injected vaccines.

          -  Persons with a history of drug or chemical abuse in the year preceding the study.

          -  Persons who received an influenza vaccine for the current influenza season or those
             who plan to receive an influenza vaccine while participating in the study.

          -  Persons who received any other vaccine within one week prior to enrollment (may delay
             enrollment).

          -  Persons who have had a respiratory illness or illness with fever within three days of
             study enrollment (may delay enrollment).

          -  Persons currently participating in another research study involving any study
             medications (medicines or vaccines).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David N Taylor, MD</last_name>
    <role>Study Director</role>
    <affiliation>VaxInnate Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2009</study_first_submitted>
  <study_first_submitted_qc>June 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2009</study_first_posted>
  <results_first_submitted>June 13, 2011</results_first_submitted>
  <results_first_submitted_qc>July 25, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 22, 2011</results_first_posted>
  <last_update_submitted>August 22, 2011</last_update_submitted>
  <last_update_submitted_qc>August 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza vaccine</keyword>
  <keyword>M2e</keyword>
  <keyword>Universal influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VAX102 IM</title>
          <description>Given as 1 µg intramuscular</description>
        </group>
        <group group_id="P2">
          <title>VAX102 SC</title>
          <description>Given as 2 µg subcutaneous</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Day 0</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Day 28</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28">2 subjects were lost to follow-up and did not receive the 2nd vaccination of 1.0 ug i.m.</participants>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VAX102 IM</title>
          <description>Given as 1 µg intramuscular</description>
        </group>
        <group group_id="B2">
          <title>VAX102 SC</title>
          <description>Given as 2 µg subcutaneous</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.3" spread="7.64"/>
                    <measurement group_id="B2" value="26.7" spread="8.74"/>
                    <measurement group_id="B3" value="27" spread="8.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Local and Systemic Symptoms Post Vaccination 1 (Day 0)</title>
        <description>Solicited local and general symptoms experienced within 7 days after vaccination 1.</description>
        <time_frame>0 to 7 days after vaccination</time_frame>
        <population>The population analyzed included all participants receiving at least 1 dose of the vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>VAX102 1.0 µg i.m.</title>
          </group>
          <group group_id="O2">
            <title>VAX102 2.0 µg s.c.</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local and Systemic Symptoms Post Vaccination 1 (Day 0)</title>
          <description>Solicited local and general symptoms experienced within 7 days after vaccination 1.</description>
          <population>The population analyzed included all participants receiving at least 1 dose of the vaccine.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-M2e Serum Antibody Concentration</title>
        <description>Anti-M2e Serum Antibody Concentration summarized by study visit using the per-protocol population.</description>
        <time_frame>42 days (+/- 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VAX102 1.0 µg i.m.</title>
          </group>
          <group group_id="O2">
            <title>VAX102 2.0 µg s.c.</title>
          </group>
        </group_list>
        <measure>
          <title>Anti-M2e Serum Antibody Concentration</title>
          <description>Anti-M2e Serum Antibody Concentration summarized by study visit using the per-protocol population.</description>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.011" lower_limit="0.007" upper_limit="0.018"/>
                    <measurement group_id="O2" value="0.012" lower_limit="0.008" upper_limit="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.376" lower_limit="0.206" upper_limit="0.685"/>
                    <measurement group_id="O2" value="0.375" lower_limit="0.241" upper_limit="0.585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.255" lower_limit="0.148" upper_limit="0.437"/>
                    <measurement group_id="O2" value="0.248" lower_limit="0.165" upper_limit="0.374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.121" lower_limit="0.744" upper_limit="1.689"/>
                    <measurement group_id="O2" value="2.062" lower_limit="1.385" upper_limit="3.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Local and Systemic Symptoms Post Vaccination 2 (Day 28)</title>
        <description>Solicited local and general symptoms experienced within 14 days after vaccination 2</description>
        <time_frame>14 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VAX102 1.0 µg i.m.</title>
          </group>
          <group group_id="O2">
            <title>VAX102 2.0 µg s.c.</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local and Systemic Symptoms Post Vaccination 2 (Day 28)</title>
          <description>Solicited local and general symptoms experienced within 14 days after vaccination 2</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were collected for 1 year following vaccination. All adverse events were collected for 42 days following vaccination.</time_frame>
      <desc>All reactogenicity findings were recorded in the CRFs. Symptoms from the Reactogenicity Memory Aid were reported as &quot;reactogenicity&quot;, and presumed to be related to the investigational product. These complaints were not additionally recorded as AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>VAX102 IM</title>
          <description>Given as 1 µg intramuscular</description>
        </group>
        <group group_id="E2">
          <title>VAX102 SC</title>
          <description>Given as 2 µg subcutaneous</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David N.Taylor</name_or_title>
      <organization>VaxInnate</organization>
      <phone>609-860-2260</phone>
      <email>david.taylor@vaxinnate.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

